Trial Profile
A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs JNJ 64152348 (Primary)
- Indications Poliomyelitis
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
- 15 Jun 2018 Status changed from recruiting to completed.
- 06 Nov 2017 Status changed from not yet recruiting to recruiting.
- 11 Sep 2017 Planned primary completion date changed from 18 Jan 2018 to 21 May 2018.